Parmax Pharma Intrinsic Value
Parmax Pharma intrinsic value. Parmax Pharma (PARMAX) median intrinsic value is ₹100.00 from 2 valuation models (range ₹55–₹100), vs current price ₹137.75 — -27.4% downside (Trading Above Calculated Value), margin of safety -37.8%. Read PARMAX dividend payout details for the complete payout history and dividend yield track record.
PARMAX Valuation Methods Summary — DCF, Graham Number & P/E
Parmax Pharma intrinsic value across 2 models vs current price ₹137.75 — upside/downside and value range per method. For current market price and key ratios, visit Parmax Pharma share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Revenue Multiple Method | revenue | ₹100.00 | ₹90.00 - ₹110.00 | -27.4% | Revenue/Share: ₹50.00, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹55.10 | ₹44.08 - ₹66.12 | -60.0% | CF Growth: 5.0%, Discount: 15% |
PARMAX Intrinsic Value vs Market Price — All Valuation Models
Parmax Pharma fair value range ₹55–₹100 vs current market price ₹137.75 across 2 valuation models. Compare with PARMAX fundamental valuation to assess whether the stock is under or overvalued.
PARMAX Intrinsic Value Analysis — Undervalued or Overvalued?
Parmax Pharma median intrinsic value ₹100.00, current price ₹137.75 — Trading Above Calculated Value by 27.4%, margin of safety -37.8%.
What is the intrinsic value of PARMAX?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Parmax Pharma (PARMAX) is ₹100.00 (median value). With the current market price of ₹137.75, this represents a -27.4% variance from our estimated fair value.
The valuation range spans from ₹55.10 to ₹100.00, indicating ₹55.10 - ₹100.00.
Is PARMAX undervalued or overvalued?
Based on our multi-method analysis, Parmax Pharma (PARMAX) appears to be trading above calculated value by approximately 27.4%.
PARMAX Financial Health — Key Ratios vs Industry Benchmarks
Parmax Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.42 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 16.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | -26.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.71x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
PARMAX Cash Flow Quality — Operating & Free Cash Flow
Parmax Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-1 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹1 Cr | ₹0 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |